menu
Grant recipient

Inge Marie Svane

Progress in Cancer Immunotherapy by Refined Management of Immune-related Toxicity & Improved fitness of Adoptive T-cell therapy
Grant amount: DKK 9,987,500
Inge Marie Svane says: “Modern immunotherapy has increased long-term survival for many cancer patients. Immunotherapy is associated with serious immune-related side effects in up to 50% of the patients including chronic and life-threatening conditions with huge negative impact on patient wellbeing and hospital resources. Knowledge on mechanisms driving the side effects and how to manage them is virtually lacking. Through this research project we aim to establish evidence-based management to improve the quality and effectiveness of health care services for the many cancer patients treated with immunotherapy. T-cell therapy has proved to be a powerful immunotherapy with efficacy in 40% and potential cure in up to 20% of melanoma patients with metastatic disease. However, T cell exhaustion and weakening by the hostile tumor environment may lead to treatment failure. This project aims to improve T cell fitness and increase tumor sensitivity for improved clinical efficacy and broader clinical usefulness.”
Inge Marie Svane
Inge Marie Svane
Professor, Department of Oncology, Herlev and Gentofte Hospital